(S)-N-(3-aminobutyl)-2-(1-(3-bromo-4-cyanophenyl)-3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)-N-isopropylacetamide | 1327336-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (S)-N-(3-aminobutyl)-2-(1-(3-bromo-4-cyanophenyl)-3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)-N-isopropylacetamide
• CAS: 1327336-87-7
• 化学式: C₂₇H₃₅BrN₄O₂
• 分子量: 527.504
• InChiKey: PVAWBELAXGNBHK-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.09
• 重原子数：
  34.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  92.12
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (S)-N-(3-aminobutyl)-2-(1-(3-bromo-4-cyanophenyl)-3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)-N-isopropylacetamide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 双氧水 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium hydroxide 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 乙醇 、 二甲基亚砜 、 甲苯 为溶剂， 生成 (16S)-5,5,9,16-tetramethyl-7,12-dioxo-13-propan-2-yl-2,13,17-triazatetracyclo[16.3.1.02,10.03,8]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide
  参考文献：
  名称：

  Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity

  摘要：

  A novel series of macrocyclic ortho-aminobenzamide Hsp90 inhibitors is reported. In continuation of our research in this area, macrocyclic amides and lactams were explored to reduce the risk of hERG liabilities. This effort culminated in the discovery of compound 38, which showed a favorable in vitro profile, and efficiently suppressed proliferation of several relevant cell lines. This compound showed prolonged Hsp90-inhibitory activity at least 24 h post-administration, consistent with elevated and prolonged exposure in the tumor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.112
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到(S)-N-(3-aminobutyl)-2-(1-(3-bromo-4-cyanophenyl)-3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-2-yl)-N-isopropylacetamide
  参考文献：
  名称：

  Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity

  摘要：

  A novel series of macrocyclic ortho-aminobenzamide Hsp90 inhibitors is reported. In continuation of our research in this area, macrocyclic amides and lactams were explored to reduce the risk of hERG liabilities. This effort culminated in the discovery of compound 38, which showed a favorable in vitro profile, and efficiently suppressed proliferation of several relevant cell lines. This compound showed prolonged Hsp90-inhibitory activity at least 24 h post-administration, consistent with elevated and prolonged exposure in the tumor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.112